Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-19-058679
Date:2019-11-29
Issuer: ODONATE THERAPEUTICS, INC. (ODT)
Original Submission Date:

Reporting Person:

O'CONNELL JOSEPH P
C/O ODONATE THERAPEUTICS, INC.
4747 EXECUTIVE DRIVE, SUITE 510 SAN DIEGO, CA 92121

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2019-11-29 A 31 a $29.22 1,560 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
EMPLOYEE STOCK OPTION (RIGHT TO BUY) 34.38 2019-11-29 deemed execution date A 31 (a) 2029-11-29 common stock 31 $34.38 31 direct
Footnotes
IDfootnote
f1 these shares were acquired on 11/29/2019 through the odonate therapeutics, inc. 2017 employee stock purchase plan in a transaction that was exempt under both rule 16b-3(d) and rule 16b-3(c).
f2 the stock options vest and becomes exercisable as follows: (i) 50% on the date of u.s. food and drug administration ("fda") approval of tesetaxel; (ii) 25% on the first anniversary of fda approval of tesetaxel; and (iii) 25% on the second anniversary of fda approval of tesetaxel. vesting is subject to the reporting person's continued service to the issuer through each vesting date.
WhaleWisdom Logo

Elevate your investments